Expanding Japanese Encephalitis Vaccination to Selected Endemic Indonesia Provinces: A Cost-effectiveness Analysis

Overview

Journal Vaccine X

Date 2022 Jul 5

PMID 35782720

Authors

Soewarta Kosen

Levina Chandra Khoe

Endang Indriasih

Ingan Tarigan

Retno Widyastuti Iriawan

Rozana Ika Agustiya

G William Letson

Elisabeth Vodicka

Affiliations

Soon will be listed here.

Abstract

Introduction: A Markov model was used to evaluate the potential health and economic impact of introducing JE vaccine nationally and in selected endemic areas of Indonesia compared to no vaccination from government and societal perspectives over a child's lifetime horizon.

Methods: Costs were obtained from hospitalized JE suspected patient billing data from 2014 to 2019 in seven provinces. Local data burden data were derived from the literature. Analysis considered several scenarios, including national and sub-regional introduction in seven provinces via a one-time vaccination campaign in all children 1-15 years old followed by routine immunization among infants (RI), or RI alone without vaccination campaign.

Results And Discussions: Across scenarios, JE vaccination was projected to range from cost-saving to cost-effective compared to no vaccination at a willingness-to-pay threshold of 0.5x gross domestic product per capita. Including a one-time campaign would avert nearly three times as many JE cases and deaths compared to RI alone while still providing good value for money.

Citing Articles

Cost-effectiveness Analysis of Japanese Encephalitis Vaccination for Children <15 Years of Age, Bangladesh.

Nguyen A, Sultana R, Vodicka E, Tasnim Z, Mehedi K, Islam M Emerg Infect Dis. 2024; 30(12):2593-2603.

PMID: 39592391 PMC: 11616670. DOI: 10.3201/eid3012.231657.

References

Bertram M, Lauer J, de Joncheere K, Edejer T, Hutubessy R, Kieny M . Cost-effectiveness thresholds: pros and cons. Bull World Health Organ. 2016; 94(12):925-930. PMC: 5153921. DOI: 10.2471/BLT.15.164418. View

Salomon J, Haagsma J, Davis A, Maertens de Noordhout C, Polinder S, Havelaar A . Disability weights for the Global Burden of Disease 2013 study. Lancet Glob Health. 2015; 3(11):e712-23. DOI: 10.1016/S2214-109X(15)00069-8. View

Marseille E, Larson B, Kazi D, Kahn J, Rosen S . Thresholds for the cost-effectiveness of interventions: alternative approaches. Bull World Health Organ. 2015; 93(2):118-24. PMC: 4339959. DOI: 10.2471/BLT.14.138206. View

Yin Z, Beeler Asay G, Zhang L, Li Y, Zuo S, Hutin Y . An economic evaluation of the use of Japanese encephalitis vaccine in the expanded program of immunization of Guizhou province, China. Vaccine. 2012; 30(37):5569-77. DOI: 10.1016/j.vaccine.2012.05.068. View

Ding D, Kilgore P, Clemens J, Wei L, Zhi-Yi X . Cost-effectiveness of routine immunization to control Japanese encephalitis in Shanghai, China. Bull World Health Organ. 2003; 81(5):334-42. PMC: 2572455. View

Touch S, Suraratdecha C, Samnang C, Heng S, Gazley L, Huch C . A cost-effectiveness analysis of Japanese encephalitis vaccine in Cambodia. Vaccine. 2010; 28(29):4593-9. DOI: 10.1016/j.vaccine.2010.04.086. View

Vodicka E, Zimmermann M, Lopez A, Silva M, Gorgolon L, Kohei T . Japanese encephalitis vaccination in the Philippines: A cost-effectiveness analysis comparing alternative delivery strategies. Vaccine. 2020; 38(13):2833-2840. PMC: 7068699. DOI: 10.1016/j.vaccine.2020.02.018. View

Campbell G, Hills S, Fischer M, Jacobson J, Hoke C, Hombach J . Estimated global incidence of Japanese encephalitis: a systematic review. Bull World Health Organ. 2011; 89(10):766-74, 774A-774E. PMC: 3209971. DOI: 10.2471/BLT.10.085233. View

Ompusunggu S, Hills S, Maha M, Moniaga V, Susilarini N, Widjaya A . Confirmation of Japanese encephalitis as an endemic human disease through sentinel surveillance in Indonesia. Am J Trop Med Hyg. 2008; 79(6):963-70. View

10.

Li X, Ma S, Liu X, Jiang L, Zhou J, Xiong Y . Immunogenicity and safety of currently available Japanese encephalitis vaccines: a systematic review. Hum Vaccin Immunother. 2015; 10(12):3579-93. PMC: 4514081. DOI: 10.4161/21645515.2014.980197. View

11.

Misra U, Kalita J . Overview: Japanese encephalitis. Prog Neurobiol. 2010; 91(2):108-20. DOI: 10.1016/j.pneurobio.2010.01.008. View

12.

Liu W, Clemens J, Kari K, Xu Z . Cost-effectiveness of Japanese encephalitis (JE) immunization in Bali, Indonesia. Vaccine. 2008; 26(35):4456-60. DOI: 10.1016/j.vaccine.2008.06.050. View

13.

Woods B, Revill P, Sculpher M, Claxton K . Country-Level Cost-Effectiveness Thresholds: Initial Estimates and the Need for Further Research. Value Health. 2016; 19(8):929-935. PMC: 5193154. DOI: 10.1016/j.jval.2016.02.017. View

14.

Leech A, Kim D, Cohen J, Neumann P . Use and Misuse of Cost-Effectiveness Analysis Thresholds in Low- and Middle-Income Countries: Trends in Cost-per-DALY Studies. Value Health. 2018; 21(7):759-761. PMC: 6041503. DOI: 10.1016/j.jval.2017.12.016. View

15.

Garjito T, Widiarti , Anggraeni Y, Alfiah S, Satoto T, Farchanny A . Japanese encephalitis in Indonesia: An update on epidemiology and transmission ecology. Acta Trop. 2018; 187:240-247. DOI: 10.1016/j.actatropica.2018.08.017. View

16.

Kari K, Liu W, Gautama K, Mammen Jr M, Clemens J, Nisalak A . A hospital-based surveillance for Japanese encephalitis in Bali, Indonesia. BMC Med. 2006; 4:8. PMC: 1481508. DOI: 10.1186/1741-7015-4-8. View

17.

Maha M, Moniaga V, Hills S, Widjaya A, Sasmito A, Hariati R . Outcome and extent of disability following Japanese encephalitis in Indonesian children. Int J Infect Dis. 2009; 13(6):e389-93. DOI: 10.1016/j.ijid.2009.01.009. View